Association of anti-PD-(L)1 treatment duration to efficacy in advanced solid tumors: a single center retrospective study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are a standard of care in multiple cancers. Only a minority benefits, thus, optimal use and treatment duration remain indistinct. While biomarkers albeit PD-L1 are scarce, declined performance status and cancer-related systemic inflammation detected by blood inflammatory markers such as C-reactive protein (CRP) have been linked to inferior prognosis.

Materials and methods

We investigated the association of limited anti-PD-(L)1 treatment duration to therapy efficacy in melanoma and non-small cell lung cancer (NSCLC) patients who received therapy in a non-curative setting in Oulu University Hospital 2014-2022. Baseline prognostic factors (e.g. ECOG, CRP, and PD-L1 for NSCLC) were collected. Progression-free (PFS), overall (OS), an

SUBMITTER: Kuusisalo S 

PROVIDER: S-EPMC11915729 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature